Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Mirae Asset Global Investments Co. Ltd. reduced its position in Alnylam Pharmaceuticals by 26.9%, owning 4,775 shares worth approximately $1.56 million following the sale of 1,759 shares in the second quarter.
• Several institutional investors have increased their stakes in Alnylam, with over 92% of the stock currently held by hedge funds and institutional investors.
• Alnylam Pharmaceuticals reported better-than-expected earnings, with a total revenue of $773.69 million for the quarter, surpassing analysts' estimates of $633.54 million, contributing to a year-over-year revenue increase of 17.3%.

Mirae Asset Global Investments Co. Ltd. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 26.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,775 shares of the biopharmaceutical company's stock after selling 1,759 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Alnylam Pharmaceuticals were worth $1,557,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the 1st quarter worth approximately $27,000. Bessemer Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the period. Washington Trust Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 53.5% in the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 61 shares during the period. Larson Financial Group LLC boosted its position in shares of Alnylam Pharmaceuticals by 77.7% in the first quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 87 shares during the period. Finally, Geneos Wealth Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 175 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Royal Bank Of Canada raised their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an "outperform" rating in a research report on Friday, September 19th. Jefferies Financial Group raised their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Evercore ISI raised their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an "outperform" rating in a report on Thursday, September 11th. JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Twenty-four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $448.04.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares of the company's stock, valued at $11,405,673.55. This represents a 8.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares of the company's stock, valued at approximately $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock valued at $44,160,261 in the last ninety days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Down 1.9%

ALNY stock opened at $450.68 on Thursday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a 50-day moving average of $448.91 and a two-hundred day moving average of $342.70. The stock has a market capitalization of $59.08 billion, a price-to-earnings ratio of -182.46 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The business's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.